Skip to main
VYGR
VYGR logo

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Voyager Therapeutics (VYGR) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 40%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Voyager Therapeutics Inc. is positioned for significant growth due to its innovative TRACER gene therapy platform, which has the potential to enable durable efficacy with a single administration while targeting severe neurological diseases. The company's robust pipeline includes several programs with promising clinical validation prospects, alongside co-commercialization options that could enhance long-term revenue potential. Furthermore, the absence of serious adverse events related to its therapies and an extended cash runway into mid-2027 allows Voyager to focus on its Alzheimer’s programs, reinforcing a favorable outlook for shareholder value creation.

Bears say

Voyager Therapeutics Inc. faces significant financial risks due to its lack of sales revenue and a protracted path to profitability, with a reported net loss of ($1.13) per share and potential delays in clinical studies that could further impact revenue projections. The company's pipeline, which includes programs like VY7523 and VY9323, is at risk due to competition from other tau antibody therapies currently in clinical development, coupled with the uncertainties surrounding their efficacy and the possibility of regulatory approval delays extending to 2033 and 2034. Additionally, any failure in meeting production needs for clinical studies or securing favorable agency decisions could substantially jeopardize Voyager's financial outlook and valuation estimates.

Voyager Therapeutics (VYGR) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 40% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Voyager Therapeutics (VYGR) Forecast

Analysts have given Voyager Therapeutics (VYGR) a Buy based on their latest research and market trends.

According to 20 analysts, Voyager Therapeutics (VYGR) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Voyager Therapeutics (VYGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.